Description

Dr. Peter Staats presents the cost-effectiveness of electrically evoked compound action potential (ECAP) spinal cord stimulation (SCS) therapy. He explains patients’ focus on functional outcomes and quality of life rather than pain scores. He discusses the background of health economics in relation to emerging therapies and the development of an economic model for assessing the cost-effectiveness of ECAP-controlled closed-loop SCS. Dr. Staats discusses the methodology of the economic analysis and the results, including the factors contributing to the superior cost-effectiveness of ECAP closed-loop SCS therapy.